These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32252747)

  • 1. Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study.
    Koguchi D; Murakami Y; Ikeda M; Dobashi M; Ishii J
    BMC Urol; 2020 Apr; 20(1):38. PubMed ID: 32252747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility of pathogens in acute uncomplicated cystitis cases in the urology department of a community hospital in Japan: Comparison with treatment outcome and hospital-wide antibiogram.
    Etani T; Naiki T; Yamaguchi S; Mori S; Nagai T; Iida K; Ando R; Kawai N; Tozawa K; Mogami T; Yasui T
    J Infect Chemother; 2017 Oct; 23(10):692-697. PubMed ID: 28807755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU).
    Wada K; Yokoyama T; Uno S; Araki M; Sadahira T; Maruyama Y; Acosta H; Nakajima H; Hiyama Y; Kunishima Y; Togo Y; Nukaya T; Yamada H; Shigemura K; Ito S; Tanimura M; Kobayashi K; Kitano H; Teishima J; Yasuda M; Uehara S; Hamasuna R; Watanabe T; Nakagawa T; Hayami H; Miyazaki J; Takahashi S; Masumori N; Ishikawa K; Kiyota H; Fujisawa M; Arakawa S; Nasu Y; Yamamoto S
    J Infect Chemother; 2021 Aug; 27(8):1169-1180. PubMed ID: 33863634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
    Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
    BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Ipekci T; Seyman D; Berk H; Celik O
    J Infect Chemother; 2014 Dec; 20(12):762-7. PubMed ID: 25179392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
    Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T; Jeinić L; Smitran A; Petković M
    Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing
    Ahn ST; Han DE; Lee DH; Kim JW; Park HS; Moon DG; Oh MM
    Investig Clin Urol; 2021 May; 62(3):310-316. PubMed ID: 33943052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].
    Aboyan IA; Orlov YN; Voloshina OA; Orlov NV; Pavlov DS
    Urologiia; 2019 Sep; (4):20-25. PubMed ID: 31535800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women.
    Matsumoto T; Muratani T; Nakahama C; Tomono K
    J Infect Chemother; 2011 Feb; 17(1):80-6. PubMed ID: 20694571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and empiric therapy.
    Uyar Aksu N; Ekinci Z; Dündar D; Baydemir C
    Pediatr Int; 2017 Feb; 59(2):176-180. PubMed ID: 27501161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series.
    Etienne M; Lefebvre E; Frebourg N; Hamel H; Pestel-Caron M; Caron F;
    BMC Infect Dis; 2014 Mar; 14():137. PubMed ID: 24612927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Causative Bacterial Strains and Sensitivityto Antimicrobial Agents in Female Acute Uncomplicated Cystitis].
    Owari T; Yamamoto T; Mizobuchi S; Itami Y; Nakahama T; Matsumoto Y; Yamada K; Momose H
    Hinyokika Kiyo; 2017 May; 63(5):189-193. PubMed ID: 28625025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical results of lividomycin in urinary tract infections].
    Saito I
    Jpn J Antibiot; 1972 Dec; 25(6):396-8. PubMed ID: 4579559
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronological change of antibiotic use and antibiotic resistance in Escherichia coli causing urinary tract infections.
    Shigemura K; Tanaka K; Adachi M; Yamashita M; Arakawa S; Fujisawa M
    J Infect Chemother; 2011 Oct; 17(5):646-51. PubMed ID: 21487942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.